Cargando…

PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer

Despite the promising activity of poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) in many cancer types with defects in the DNA damage response the majority of the treated patients acquire PARPi resistance and succumb to their diseases. Consequently, there is an urgent need to identify the mech...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martincuks, Antons, Song, Jieun, Kohut, Adrian, Zhang, Chunyan, Li, Yi-Jia, Zhao, Qianqian, Mak, Edward, Rodriguez-Rodriguez, Lorna, Yu, Hua, Cristea, Mihaela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693573/ https://www.ncbi.nlm.nih.gov/pubmed/34956861 http://dx.doi.org/10.3389/fonc.2021.724104

Ejemplares similares

CD44 in Ovarian Cancer Progression and Therapy Resistance—A Critical Role for STAT3
por: Martincuks, Antons, et al.
Publicado: (2020)

Niraparib-induced STAT3 inhibition increases its antitumor effects
por: Zhao, Qianqian, et al.
Publicado: (2022)

STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
por: Ding, Liya, et al.
Publicado: (2023)

Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer
por: Girda, Eugenia, et al.
Publicado: (2022)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
por: Huang, Xuan-zhang, et al.
Publicado: (2020)

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
por: Tang, Bin, et al.
Publicado: (2023)

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
por: Franzese, Elisena, et al.
Publicado: (2020)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
por: Jiang, Yifan, et al.
Publicado: (2020)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
por: Turinetto, Margherita, et al.
Publicado: (2021)

PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets
por: Shah, Girish M., et al.
Publicado: (2013)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells
por: Jia, Yaxun, et al.
Publicado: (2022)

PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials
por: Wang, Yizi, et al.
Publicado: (2020)

Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Ren, Ning, et al.
Publicado: (2021)

Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report
por: Bian, Yuan, et al.
Publicado: (2022)

Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report
por: Qian, Bing, et al.
Publicado: (2022)

Role of Biomarkers in the Development of PARP Inhibitors
por: Ganguly, Bratati, et al.
Publicado: (2016)

Structural Implications for Selective Targeting of PARPs
por: Steffen, Jamin D., et al.
Publicado: (2013)

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Xu, Yangchun, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Wang, Hongmei, et al.
Publicado: (2021)

Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment
por: Chilà, Rosaria, et al.
Publicado: (2022)

Adenosine receptor A2b confers ovarian cancer survival and PARP inhibitor resistance through IL‐6‐STAT3 signalling
por: Chi, Liqing, et al.
Publicado: (2023)

Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors
por: Mekonnen, Negesse, et al.
Publicado: (2022)

High Expression of PARP1 in Tumor and Stroma Cells Predicts Different Prognosis and Platinum Resistance in Patients With Advanced Epithelial Ovarian Cancer
por: Zuo, Wei-Wei, et al.
Publicado: (2022)

Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer
por: Zuo, Wei-Wei, et al.
Publicado: (2023)

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
por: Reinbolt, Raquel E., et al.
Publicado: (2013)

Successes and Challenges of PARP Inhibitors in Cancer Therapy
por: Ricks, Tiffany K., et al.
Publicado: (2015)

Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
por: Elli, Elena Maria, et al.
Publicado: (2019)

Editorial: Inhibiting PARP as a Strategic Target in Cancer
por: Zorn, Kristin K., et al.
Publicado: (2016)

PARP14 is a PARP with both ADP-ribosyl transferase and hydrolase activities
por: Đukić, Nina, et al.
Publicado: (2023)

Immunosuppressive Microenvironment in Neuroblastoma
por: Pistoia, Vito, et al.
Publicado: (2013)

PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality
por: Yakovlev, Vasily A., et al.
Publicado: (2023)

Beyond DNA Repair: Additional Functions of PARP-1 in Cancer
por: Weaver, Alice N., et al.
Publicado: (2013)

PET Imaging of PARP Expression Using (18)F-Olaparib
por: Wilson, Thomas C., et al.
Publicado: (2019)

Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
por: Vikas, Praveen, et al.
Publicado: (2020)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ecj4lph8rn5ju470nma3rm4qvh